🟠 Moderate Evidence
A new clinical trial published in the New England Journal of Medicine (June 2026) reports on the optimal timing of percutaneous coronary intervention (PCI) for non-culprit lesions in patients with acute myocardial infarction, challenging the widespread practice of treating multiple blocked coronary arteries during the same procedure. The trial examined whether waiting days or weeks to treat secondary blockages yields better patient outcomes than immediate intervention.
Key takeaways
- Timing of treatment for secondary coronary blockages in heart attack patients remains contested; immediate intervention was the standard approach but now faces evidence-based scrutiny
- The trial compares immediate nonculprit-lesion PCI (during the acute hospitalization) against deferred PCI (performed after initial stabilization), addressing a critical gap in clinical guidance
- Study findings may reshape cardiology practice across Europe and internationally, particularly regarding resource allocation and procedural scheduling in acute cardiac care
Study at a Glance
| Source | New England Journal of Medicine |
| Study type | Randomized controlled trial (RCT) |
| Population | Patients with acute myocardial infarction and multivessel coronary artery disease |
| Intervention comparison | Immediate nonculprit-lesion PCI versus deferred PCI |
| Publication date | June 25, 2026 (Volume 394, Issue 24) |
Clinical Decision Point: Timing of Secondary Vessel Treatment in Multivessel Myocardial Infarction
Two evidence-based approaches to managing nonculprit-lesion coronary artery disease following acute myocardial infarction
Source: New England Journal of Medicine, June 2026 | Georgian Medical Journal News
The Clinical Challenge: Multiple Blockages in a Single Heart Attack
Acute myocardial infarction (AMI) frequently occurs in patients with multivessel coronary artery disease—multiple narrowed or blocked vessels feeding the heart muscle. Historically, cardiologists focused interventional efforts on the primary culprit lesion causing the acute event, leaving secondary blockages for later treatment. However, over the past decade, immediate intervention on all identified significant lesions has gained traction as a strategy potentially reducing long-term complications.
The rationale for immediate treatment is intuitive: remove all obstructions in one procedure, minimize patient risk from a second intervention, and restore blood flow comprehensively. Yet this approach carries its own risks. During acute myocardial infarction, the heart is metabolically stressed, vessel walls are inflamed, and the patient’s physiological state is unstable. Extending procedure time or adding interventional complexity might trigger complications such as contrast-induced kidney injury, stent thrombosis, or hemodynamic collapse.
Why This Trial Matters: Addressing a Critical Evidence Gap
The New England Journal of Medicine publication (June 2026, Volume 394, Issue 24) represents a high-quality randomized comparison of these two competing strategies. Prior evidence has been mixed: some observational studies favored immediate treatment, while others suggested deferred intervention (performed after the acute phase, typically 3–7 days later) allowed the heart to stabilize and reduced acute procedural complications.
This trial fills that evidence gap by randomizing patients with acute myocardial infarction and multivessel disease to either immediate or deferred nonculprit-lesion PCI. The randomized design eliminates selection bias and confounding that plague observational comparisons. Cardiologists across Clinical Updates networks and beyond have awaited such definitive guidance, as current international guidelines remain nonuniform on timing recommendations.
The trial directly compares immediate versus deferred treatment of secondary coronary blockages in acute myocardial infarction, addressing a pivotal question in interventional cardiology practice.
— New England Journal of Medicine, June 2026
What the Evidence Reveals About Procedural Timing
While the full trial results were published in June 2026, the core comparison hinges on patient outcomes measured over a follow-up period typically ranging from 1 to 3 years. Key endpoints in such trials typically include death, recurrent myocardial infarction, unplanned revascularization, and heart failure hospitalization. The timing question is particularly relevant for healthcare systems managing high acute MI volumes, where procedural scheduling and resource allocation depend critically on evidence-based guidance.
Immediate PCI proponents argue that treating all lesions during one catheterization session reduces cumulative radiation exposure, contrast administration, and psychological burden on patients facing two procedures. Deferred PCI advocates counter that allowing the acute inflammatory phase to resolve (24–72 hours post-AMI) reduces procedural complications and permits better assessment of lesion hemodynamic significance, avoiding unnecessary intervention on borderline stenoses that may not require treatment.
The trial methodology likely incorporated objective criteria for defining hemodynamic significance—such as fractional flow reserve (FFR) measurement—to guide decisions about which nonculprit lesions warrant intervention. This physiologic approach contrasts with older angiography-only visual assessment and represents current international best practice.
Implications for Cardiology Practice and Patient Care
Publication in the New England Journal of Medicine signals that these findings will rapidly influence clinical practice. The journal’s visibility ensures dissemination to cardiology departments, interventional training programs, and guideline-writing committees globally. If deferred PCI proves noninferior or superior to immediate intervention—particularly on hard endpoints like mortality or recurrent infarction—current practice patterns will shift substantially.
Health systems will reassess catheterization laboratory scheduling, training emphasis, and staffing models. Some institutions have structured acute MI protocols around same-day multivessel PCI; evidence favoring deferral would require workflow redesign. Conversely, if immediate intervention maintains superior outcomes on safety measures, current practice receives validation, and debates about procedural timing may focus instead on operator experience and patient-selection criteria.
The trial’s impact extends to Health Policy and guideline development. The European Society of Cardiology, American College of Cardiology, and other standard-setting bodies will incorporate these data into updated recommendations for acute MI management. Georgia’s National Center for Disease Control and Cardiology Society will likewise evaluate applicability to local healthcare settings and cardiac care protocols.
What this means
Frequently asked questions
What is a nonculprit lesion in myocardial infarction?
The culprit lesion is the primary blockage that caused the acute heart attack. A nonculprit lesion is a secondary narrowing or blockage in a different coronary artery that does not directly trigger the acute event but increases long-term cardiovascular risk. The trial examines whether treating this secondary blockage immediately or days later yields better outcomes.
Why is timing of the second intervention controversial?
Immediate intervention simplifies logistics and reduces patients’ need for a second procedure, but risks extending the acute intervention during a physiologically unstable period. Deferred intervention allows the heart to stabilize and inflammation to subside, potentially reducing acute complications, but requires a second hospitalization and carries time-dependent risk of recurrent symptoms.
How will this trial change cardiology practice?
If evidence supports deferred intervention, cardiology departments will restructure acute MI protocols to perform culprit-lesion-only PCI during hospitalization, then schedule nonculprit PCI as a planned procedure days later. Training emphasis will shift toward risk stratification and FFR-guided decision-making, and catheterization laboratory scheduling will reflect this two-stage approach.
The June 2026 publication of this randomized trial in the New England Journal of Medicine marks a watershed moment for acute myocardial infarction management. Cardiologists, interventional teams, and healthcare administrators must now integrate these data into clinical decision-making, updating protocols and training to reflect evidence-based timing of nonculprit-lesion intervention. For patients with multivessel disease presenting with acute myocardial infarction, the promise is more personalized, safer, and ultimately more effective revascularization strategies grounded in rigorous clinical evidence.
Source: Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction, New England Journal of Medicine, June 25, 2026, Volume 394, Issue 24
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
